Sirtex Medical
Sirtex Medical Limited is a life-sciences company based in North Sydney, Australia, specializing in the development and delivery of innovative oncology treatments. The company focuses on using novel small particle technology, specifically through its principal product, SIR-Spheres Y-90 resin microspheres. This targeted radioactive treatment is designed for patients suffering from primary and secondary metastatic liver cancer, utilizing selective internal radiation therapy (SIRT) to deliver treatment directly to the liver. With operations extending across the Asia-Pacific, Europe, the Middle East, Africa, and both North and South America, Sirtex Medical aims to enhance treatment options and outcomes for liver cancer patients globally. Since September 2018, Sirtex has operated as a subsidiary of CDH Genetech Limited.
1 past transactions
Nanospectra Biosciences
Series B in 2020
Nanospectra Biosciences, Inc. is a medical device company based in Houston, Texas, that specializes in developing and commercializing particle-based therapies aimed at the selective and precise thermal destruction of solid tumors. The company's flagship product, AuroLase Therapy, employs AuroShell nanoparticles, which are designed for effective thermal ablation while minimizing damage to surrounding healthy tissue and preserving critical structures. In addition to AuroLase Therapy, Nanospectra offers research-use-only nanoparticles with distinct optical characteristics, including gold nanoshells, as well as custom production products tailored for various medical and commercial applications. Founded in 2002, Nanospectra Biosciences is dedicated to advancing innovative therapies in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.